Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing

The clinical utility and outcomes of MCED testing for screening and early detection still lack comprehensive evidence. Nonetheless, this simulation model facilitates a thorough analysis of MCED tests within the Australian healthcare context, providing insights into potential additional detections and costs to the healthcare system, which may help prioritise future evidence development. The adaptable yet novel SD model presented herein is anticipated to be of considerable interest to industry, policymakers, consumers and clinicians involved in informing clinical and economic decisions regarding integrating MCED tests as cancer screening and early detection tools. The expected results of applying this SD model will determine whether using MCED testing in conjunction with SOC screening offers any potential benefits, possibly guiding policy decisions and clinical practices towards the adoption of MCED tests.

Authors

Institutions

Publication Details

Journal
PharmacoEconomics - Open
Published
2024-10-18
DOI
https://doi.org/10.1007/s41669-024-00533-3
Citations
3
Primary Topic
Genetics, Bioinformatics, and Biomedical Research
Type
article
Field-Weighted Citation Impact
0.70
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing

Maarten J. IJzerman, Hadi Akbarzadeh Khorshidi, Özge Karanfil, Stephen Q. Wong et al.
3 citations
PharmacoEconomics - Open
Genetics, Bioinformatics, and Biomedical Research
0.70
article

Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing

Maarten J. IJzerman, Hadi Akbarzadeh Khorshidi, Özge Karanfil, Stephen Q. Wong, Jon Emery, Mussab Fagery
article en
3 citations

Abstract

The clinical utility and outcomes of MCED testing for screening and early detection still lack comprehensive evidence. Nonetheless, this simulation model facilitates a thorough analysis of MCED tests within the Australian healthcare context, providing insights into potential additional detections and costs to the healthcare system, which may help prioritise future evidence development. The adaptable yet novel SD model presented herein is anticipated to be of considerable interest to industry, policymakers, consumers and clinicians involved in informing clinical and economic decisions regarding integrating MCED tests as cancer screening and early detection tools. The expected results of applying this SD model will determine whether using MCED testing in conjunction with SOC screening offers any potential benefits, possibly guiding policy decisions and clinical practices towards the adoption of MCED tests.

PharmacoEconomics - OpenVol. 9(1)
Koç University (TR), The University of Melbourne (AU), Peter MacCallum Cancer Centre (AU), Melbourne Health (AU), Erasmus University Rotterdam (NL)
Openalex Percentile: Top 29%
Genetics, Bioinformatics, and Biomedical Research
0.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing — Maarten J. IJzerman, Hadi Akbarzadeh Khorshidi, et al. · PharmacoEconomics - Open (2024) | TGRS Research Map | TGRS